Skip to content
Screener

Xenon Pharmaceuticals XENE Q1 2025 earnings

Reported May 12, 2025 · After market close

Revenue$7.5MBeat by $5.6M
EPS-$0.83Beat by $0.11
Revenue estimate$1.9M
EPS estimate-$0.94

Next report

Nov 2, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$1.17

Financials

Q1 2025

Income statement

See full
Revenue$7.5M—
Operating income-$72.7M-23.2%
Net income-$65.0M-35.7%
EPS (diluted)-$0.83-33.9%

Balance sheet

See full
Cash & equivalents$116.7M+98.1%
Total debt$8.7M-16.8%
Total equity$704.0M-20.7%
Total assets$743.3M-19.1%

Cash flow

See full
Operating cash flow-$61.7M-33.5%
CapEx$43.0K-77.1%
Free cash flow-$61.7M-33.0%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.57B-14.7%
Enterprise value$2.46B-17.0%
P/S342.4×—

Profitability

See full
Operating margin-3,906.6%—
Net margin-3,352.6%—
FCF margin-2,663.8%—

Returns & leverage

See full
Return on equity-31.6%+14.8pp
Debt / equity0×0.0×
Current ratio17.7×-14.2×

Versus estimates

Revenue

Q1 2025$7.5MBeat by $5.6M

Diluted EPS

Q2 2026-$1.11Beat by $0.03Q1 2026-$1.17In lineQ4 2025-$1.31Miss by $0.11Q3 2025-$1.15Beat by $0.01Q2 2025-$1.07Miss by $0.04
Q1 2025-$0.83Beat by $0.11

FAQ

When did Xenon Pharmaceuticals report Q1 2025 earnings?
Xenon Pharmaceuticals (XENE) reported Q1 2025 earnings on May 12, 2025 after market close.
What were Xenon Pharmaceuticals's Q1 2025 revenue and EPS?
Xenon Pharmaceuticals reported revenue of $7.5M and eps of $-0.83 for Q1 2025.
Did Xenon Pharmaceuticals beat estimates in Q1 2025?
Revenue beat the consensus estimate of $1.9M by $5.6M. EPS beat the consensus estimate of $-0.94 by $0.11.
How did Xenon Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 33.9% from $-0.62.
Where can I find Xenon Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-069183) and the 10-Q periodic report (0000950170-25-069342) directly on SEC EDGAR. The filing index links above go to sec.gov.